Astrana Health Inc (ASTH)vsJohnson & Johnson (JNJ)
ASTH
Astrana Health Inc
$36.67
-0.73%
HEALTHCARE · Cap: $1.83B
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2484% more annual revenue ($99.33B vs $3.84B). JNJ leads profitability with a 16.2% profit margin vs 1.1%. JNJ trades at a lower P/E of 38.8x. JNJ earns a higher WallStSmart Score of 57/100 (C).
ASTH
Buy56
out of 100
Grade: C
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASTH.
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 48.5% year-over-year
Earnings expanding 110.5% YoY
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.8% — below average capital efficiency
1.1% margin — thin
Operating margin of 3.5%
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ASTH
The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 48.5% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : ASTH
The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 44.4x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ASTH profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
ASTH carries more volatility with a beta of 1.03 — expect wider price swings.
ASTH is growing revenue faster at 48.5% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 56/100), backed by strong 16.2% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Astrana Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?